Physician profile
Joseph Leanza
NPI 1154476869
$2,994.28
in general payments reported to CMS, 2019-2025
23 companies · $592 in 2025
The $592 reported for 2025 was more than what 95% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $359 · 2020: $133 · 2021: $235 · 2022: $339 · 2023: $498 · 2024: $838 · 2025: $592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,928.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,928.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $449.91 | 2022-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $414.81 | 2019-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $410.63 | 2022-2025 | Qelbree, Qelbree |
| Tris Pharma INC | $318.67 | 2019-2024 | Dyanavel Xr |
| Noven Therapeutics, LLC | $187.04 | 2023-2025 | Xelstrym |
| Pfizer INC. | $180.88 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $143.21 | 2019-2025 | Vaxelis, Vaxneuvance, Gardasil 9 |
| Collegium Pharmaceutical, INC. | $123.53 | 2025 | Jornay Pm |
| Kaleo, INC. | $115.51 | 2019-2024 | Auvi-Q |
| Takeda Pharmaceuticals U.S.A., INC. | $103.48 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $99.31 | 2024-2025 | |
| Adlon Therapeutics L.P. | $79.43 | 2019-2020 | |
| Glaxosmithkline, LLC. | $72.88 | 2019-2025 | Bexsero |
| Neos Therapeutics, Lp | $68.60 | 2019-2025 | Cotempla Xr-Odt, Adzenys Xr-Odt |
| Seqirus USA INC | $55.11 | 2022-2024 | Flucelvax |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $30.30 | 2019 | |
| Shire North American Group INC | $27.29 | 2019 | |
| Alk-Abello, INC | $23.69 | 2025 | Neffy, Grastek, Odactra |
| Biomerieux INC | $19.90 | 2025 | |
| Rhodes Pharmaceuticals L.P. | $19.68 | 2019 | |
| Alexion Pharmaceuticals, INC. | $18.00 | 2019 | |
| Cranial Technologies, INC | $16.52 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $15.90 | 2024 | Flumist Quadrivalent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Leanza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.